基于网络药理学、分子对接和体外细胞实验研究白花蛇舌草总黄酮对食管鳞癌的作用机制
Mechanistic Investigation of Total Flavonoids from Hedyotis diffusa Willd. in Esophageal Squamous Cell Carcinoma via Network Pharmacology, Molecular Docking, and in Vitro Cell Experiments
摘要: 目的:借助网络药理学与分子对接方法,探究白花蛇舌草总黄酮抗食管鳞癌的作用机制,并通过体外细胞实验进行验证,为后续研究提供依据。方法:借助TCMSP获取白花蛇舌草的药物靶点,从GeneCards、TTD和OMIM数据库筛选食管鳞癌相关靶点,并利用Veen图获取其交集靶点;应用Cytoscape 3.10.2构建PPI网络,进行GO与KEGG富集分析;进一步将活性成分槲皮素(Quercetin)与核心靶点蛋白进行分子对接,并通过体外细胞实验验证作用效果。结果:共筛选出127个交集靶点,包括NFKB1、EGF、TP53、ERBB2等,确定Quercetin为有效成分。主要调控NFKB1、TP53及EGF信号通路发挥抗肿瘤作用。分子对接实验显示其与核心靶点结合良好;细胞实验表明白花蛇舌草总黄酮浓度提升会抑制食管鳞癌细胞存活。结论:白花蛇舌草总黄酮的抗肿瘤作用可能与其调控NFKB1与TP53等靶点相关。
Abstract: Objective: To investigate the mechanism of action of total flavonoids from Hedyotis diffusa Willd. (HF) against esophageal squamous cell carcinoma (ESCC) using network pharmacology and molecular docking methods, and to verify the effect through in vitro cell experiments, so as to provide a basis for subsequent research. Methods: The drug targets of Hedyotis diffusa were obtained from TCMSP. ESCC-related targets were screened from GeneCards, TTD, and OMIM databases, and the intersection targets were identified using a Venn diagram. Cytoscape 3.10.2 was used to construct a protein-protein interaction (PPI) network, followed by Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses. Furthermore, molecular docking was performed between the active component quercetin and core target proteins, and the effect was verified by in vitro cell experiments. Results: A total of 127 intersection targets were screened, including NFKB1, EGF, TP53, ERBB2, etc., and quercetin was identified as the effective component. It exerts anti-tumor effects mainly by regulating NFKB1, TP53, and EGF signaling pathways. Molecular docking experiments showed that quercetin binds well to core targets; cell experiments indicated that the inhibitory effect of HF on the viability of ESCC cells is concentration-dependent. Conclusion: The anti-tumor effect of total flavonoids from Hedyotis diffusa may be associated with their regulation of targets such as NFKB1 and TP53.
文章引用:肖思哲, 陈慧芳, 周庄, 黄浩博, 李让, 陈晓冰. 基于网络药理学、分子对接和体外细胞实验研究白花蛇舌草总黄酮对食管鳞癌的作用机制[J]. 临床医学进展, 2026, 16(2): 281-294. https://doi.org/10.12677/acm.2026.162391

参考文献

[1] 李科汛. 胸段食管鳞癌淋巴结清扫强度与预后的相关性研究[D]: [硕士学位论文]. 成都: 电子科技大学, 2023.
[2] 刘欣. 基于液体活检的cfDNA甲基化在食管癌早期诊断的临床应用价值分析[D]: [硕士学位论文]. 长春: 吉林大学, 2024.
[3] 李昌顶. 70岁以上食管鳞癌治疗效果及预后因素比较研究[D]: [硕士学位论文]. 泸州: 西南医科大学, 2024.
[4] 陈令媛. 健脾消膈方联合TP方案化疗治疗中晚期食管鳞癌的临床研究[D]: [硕士学位论文]. 南京: 南京中医药大学, 2022.
[5] 蒋雷. 中老年患者肠道微生态与食管鳞癌的关系[D]: [硕士学位论文]. 大连: 大连医科大学, 2021.
[6] 潘冠华. NF-κB促进食管鳞癌血管生长和食管癌细胞增殖、侵袭的研究[D]: [硕士学位论文]. 乌鲁木齐: 新疆医科大学, 2024.
[7] Qian, K., Fu, D., Jiang, B., Wang, Y., Tian, F., Song, L., et al. (2021) Mechanism of Hedyotis diffusa in the Treatment of Cervical Cancer. Frontiers in Pharmacology, 12, Article 808144. [Google Scholar] [CrossRef] [PubMed]
[8] 秦凌峰. 白花蛇舌草化学成分及药理活性研究[D]: [硕士学位论文]. 北京: 北京协和医学院, 2024.
[9] Zhang, R., Ma, C., Wei, Y., Wang, X., Jia, J., Li, J., et al. (2021) Isolation, Purification, Structural Characteristics, Pharmacological Activities, and Combined Action of Hedyotis diffusa Polysaccharides: A Review. International Journal of Biological Macromolecules, 183, 119-131. [Google Scholar] [CrossRef] [PubMed]
[10] 王雪, 夏顺利, 刘景楠, 等. 白花蛇舌草总黄酮大孔树脂纯化工艺及其体内抑瘤作用的研究[J]. 中医药信息, 2021, 38(3): 16-21.
[11] Huang, L., Xu, H., Wu, T. and Li, G. (2021) Hedyotis diffusa Willd. Suppresses Hepatocellular Carcinoma via Downregulating Akt/mTOR Pathways. Evidence-Based Complementary and Alternative Medicine, 2021, Article ID: 5210152. [Google Scholar] [CrossRef] [PubMed]
[12] Wu, Z., Yin, B. and You, F. (2022) Molecular Mechanism of Anti-Colorectal Cancer Effect of Hedyotis diffusa Willd and Its Extracts. Frontiers in Pharmacology, 13, Article 820474. [Google Scholar] [CrossRef] [PubMed]
[13] 徐应怡, 汪子贵, 尚瑞鹏, 等. 纳米粒递送中药活性成分在癌症治疗中的应用研究进展[J]. 天津中医药大学学报, 2025, 44(7): 661-672.
[14] Vinayak, M. and Maurya, A.K. (2019) Quercetin Loaded Nanoparticles in Targeting Cancer: Recent Development. Anti-Cancer Agents in Medicinal Chemistry, 19, 1560-1576. [Google Scholar] [CrossRef] [PubMed]
[15] 程旭, 谢智锋, 施向敏, 等. 基于网络药理学和实验验证探讨槲皮素增敏乳腺癌治疗作用机制研究[J]. 现代药物与临床, 2025, 40(4): 845-853.
[16] 胡永进, 李凤娥. 槲皮素调节PD-1/PD-L1信号通路对胃癌细胞免疫逃逸的影响[J]. 中国免疫学杂志, 2025, 41(8): 1965-1969.
[17] 韩惠杰, 刘辉, 赵永波, 等. 基于网络药理学和实验验证探讨槲皮素通过p53信号通路抗结直肠癌的作用机制[J]. 山东科学, 2025, 38(1): 32-43.
[18] Crombet Ramos, T., Santos Morales, O., Dy, G.K., León Monzón, K. and Lage Dávila, A. (2021) The Position of EGF Deprivation in the Management of Advanced Non-Small Cell Lung Cancer. Frontiers in Oncology, 11, Article 639745. [Google Scholar] [CrossRef] [PubMed]
[19] Darmadi, D., Aminov, Z., Hjazi, A., Roopashree, R., Kazmi, S.W., Mustafa, Y.F., et al. (2024) Investigation of the Regulation of EGF Signaling by miRNAs, Delving into the Underlying Mechanism and Signaling Pathways in Cancer. Experimental Cell Research, 442, Article ID: 114267. [Google Scholar] [CrossRef] [PubMed]
[20] Luo, Y., Wang, D., Gong, T. and Zhu, J. (2016) An Updated Meta-Analysis of 37 Case-Control Studies on the Association between NFKB1-94ins/del ATTG Promoter Polymorphism and Cancer Susceptibility. Oncotarget, 7, 58659-58670. [Google Scholar] [CrossRef] [PubMed]
[21] Voce, D.J., Schmitt, A.M., Uppal, A., McNerney, M.E., Bernal, G.M., Cahill, K.E., et al. (2014) Nfkb1 Is a Haploinsufficient DNA Damage-Specific Tumor Suppressor. Oncogene, 34, 2807-2813. [Google Scholar] [CrossRef] [PubMed]
[22] Voskarides, K. and Giannopoulou, N. (2023) The Role of TP53 in Adaptation and Evolution. Cells, 12, Article 512. [Google Scholar] [CrossRef] [PubMed]
[23] Zhong, L., Li, H., Chang, W., Ao, Y., Wen, Z. and Chen, Y. (2023) TP53 Mutations in Esophageal Squamous Cell Carcinoma. Frontiers in Bioscience-Landmark, 28, Article 219. [Google Scholar] [CrossRef] [PubMed]